Allison Wheeler, MD, explores the transformative journey of hemophilia A treatment, from blood products to advanced recombinant factor therapies, longer half-life products, and subcutaneous injections, that have revolutionized care.
New research by RCSI University of Medicine and Health Sciences published in Blood journal has revealed that the age at which individuals are tested for von Willebrand disease (VWD), a common bleeding disorder, significantly affects their diagnosis.
Explore the prevalence of hemophilia A in the United States and its profound clinical impact on patients, delving into the challenges and implications of managing this bleeding disorder. Additionally, gain valuable insights into the economic costs associated with the comprehensive care required for individuals with hemophilia A, shedding light on the financial burdens faced by both patients and healthcare systems.
Lisa Schrade, PharmD, and Robert Sidonio Jr, MD, MSc, explore the integral partnership between specialty pharmacists and hematologists in managing patients with hemophilia.
While clinical trials offer controlled data, real-world studies like HEM-POWR bridge gaps, confirming damoctocog alfa pegol’s effectiveness and tolerance, establishing it as a valuable hemophilia A treatment option.